<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:description xml:lang="eng">There is scant literature on primary nonhematopoietic malignant liver tumours (PMLT) in cats. In this retrospective study, medical data of 40 cats diagnosed with PMLT were reviewed over a period of 22 years (2000–2021). The most frequent epithelial tumours were hepatocellular (42.5%) and bile duct carcinomas (32.5%), only six (15%) cats had mesenchymal tumours. The median age was 13 years and clinical signs commonly included ano-/hyporexia (62.5%), apathy/lethargy (52.5%), weight loss (42.5%) and vomiting (35%). At initial diagnosis, metastases were confirmed in 1 (2.5%) and suspected in three (7.5%) cats. Massive was the most frequent morphology (75%). Most intrahepatic tumours were left-sided (54.2%) with the left medial lobe being primarily affected (25%). Extrahepatic tumours were rare (5%). In 34 (85%) cats, liver lobectomy was performed (surgery group), four (10%) were treated palliatively (non-surgery group), and two (5%) received no treatment. Intraoperative complications occurred in 11.8% with four (15.4%) postoperative deaths. Recurrence was detected in 28.6% at a median of 151 days (range, 79–684 days), while postoperative metastases were suspected in 21.4% at a median of 186 days (range, 79–479 days). The median survival time (MST) was significantly longer in cats of the surgery group (375 days) than in the non-surgery group (16 days) (p = .002). MST was 868 days for hepatocellular compared to 270 days for bile duct carcinomas (p = .06). In summary, liver lobectomy is associated with prolonged survival times and good prognosis in cats with hepatocellular, and an acceptable prognosis in cats with bile duct carcinoma.</dc:description>
  <dc:subject xml:lang="eng">Cats</dc:subject>
  <dc:subject xml:lang="eng">Animals</dc:subject>
  <dc:subject xml:lang="eng">Retrospective Studies</dc:subject>
  <dc:subject xml:lang="eng">Prognosis</dc:subject>
  <dc:subject xml:lang="eng">Weight Loss</dc:subject>
  <dc:subject xml:lang="eng">Liver Neoplasms Surgery</dc:subject>
  <dc:subject xml:lang="eng">Liver Neoplasms Veterinary</dc:subject>
  <dc:subject xml:lang="eng">Carcinoma Veterinary</dc:subject>
  <dc:subject xml:lang="eng">Cat Diseases Diagnosis</dc:subject>
  <dc:subject xml:lang="eng">Cat Diseases Surgery</dc:subject>
  <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
  <dc:title xml:lang="eng">Feline primary nonhematopoietic malignant liver tumors: A multicenter retrospective study (2000-2021)</dc:title>
  <dc:source xml:lang="eng">Veterinary and Comparative Oncology</dc:source>
  <dc:format>application/pdf</dc:format>
  <dc:creator>Viktoria Brandstetter</dc:creator>
  <dc:creator>Jarno M Schmidt</dc:creator>
  <dc:creator>Laurent Findji</dc:creator>
  <dc:creator>Laura E. Selmic</dc:creator>
  <dc:creator>Daniela Murgia</dc:creator>
  <dc:creator>Carlos H de Mello Souza</dc:creator>
  <dc:creator>Lea M Liehmann</dc:creator>
  <dc:creator>Henry L&#39; Eplattenier</dc:creator>
  <dc:creator>Alexander Tichy</dc:creator>
  <dc:creator>Simona Vincenti</dc:creator>
  <dc:language>eng</dc:language>
  <dc:type xml:lang="ita">Testo</dc:type>
  <dc:type xml:lang="ita">Articolo di rivista</dc:type>
  <dc:rights xml:lang="eng">© 2023 The Authors</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:publisher>Wiley</dc:publisher>
  <dc:date>2023</dc:date>
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:identifier>doi:10.1111/vco.12874</dc:identifier>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:4228</dc:identifier>
</oai_dc:dc>